Trial Profile
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2014
Price :
$35
*
At a glance
- Drugs R 348 (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Rigel Pharmaceuticals
- 24 Dec 2014 New trial record